AU2016348847B2 - Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor - Google Patents

Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor Download PDF

Info

Publication number
AU2016348847B2
AU2016348847B2 AU2016348847A AU2016348847A AU2016348847B2 AU 2016348847 B2 AU2016348847 B2 AU 2016348847B2 AU 2016348847 A AU2016348847 A AU 2016348847A AU 2016348847 A AU2016348847 A AU 2016348847A AU 2016348847 B2 AU2016348847 B2 AU 2016348847B2
Authority
AU
Australia
Prior art keywords
ethyl
carboxylate
piperidin
azepane
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016348847A
Other languages
English (en)
Other versions
AU2016348847A1 (en
Inventor
Giles Albert Brown
Benjamin Gerald TEHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of AU2016348847A1 publication Critical patent/AU2016348847A1/en
Application granted granted Critical
Publication of AU2016348847B2 publication Critical patent/AU2016348847B2/en
Assigned to NXERA PHARMA UK LIMITED reassignment NXERA PHARMA UK LIMITED Request to Amend Deed and Register Assignors: HEPTARES THERAPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016348847A 2015-11-02 2016-11-02 Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor Active AU2016348847B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1519352.7 2015-11-02
GBGB1519352.7A GB201519352D0 (en) 2015-11-02 2015-11-02 Pharmaceutical compounds
PCT/GB2016/053396 WO2017077292A1 (en) 2015-11-02 2016-11-02 Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor

Publications (2)

Publication Number Publication Date
AU2016348847A1 AU2016348847A1 (en) 2018-06-07
AU2016348847B2 true AU2016348847B2 (en) 2021-07-08

Family

ID=55130557

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016348847A Active AU2016348847B2 (en) 2015-11-02 2016-11-02 Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor

Country Status (10)

Country Link
US (2) US11208396B2 (enExample)
EP (2) EP3370828B1 (enExample)
JP (1) JP6799596B2 (enExample)
CN (1) CN108290055B (enExample)
AU (1) AU2016348847B2 (enExample)
CA (1) CA3003669C (enExample)
DK (1) DK3370828T3 (enExample)
ES (1) ES2804774T3 (enExample)
GB (1) GB201519352D0 (enExample)
WO (1) WO2017077292A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831541B (zh) 2011-11-18 2019-09-06 赫普泰雅治疗有限公司 毒蕈碱性m1受体激动剂
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017112719A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
US11149022B2 (en) 2017-10-17 2021-10-19 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP2021503443A (ja) * 2017-10-31 2021-02-12 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
KR102798432B1 (ko) 2019-10-09 2025-04-22 노파르티스 아게 M4 작용제로서의 5-옥사-2-아자스피로[3.4]옥탄 유도체
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072705A1 (en) * 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
WO2014045031A1 (en) * 2012-09-18 2014-03-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
WO2014122474A1 (en) * 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2015118342A1 (en) * 2014-02-06 2015-08-13 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
WO1996013262A1 (en) 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU7478496A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
ATE311377T1 (de) 1996-08-26 2005-12-15 Pfizer Spirocyclische dopaminrezeptor-subtyp-liganden
WO1998057641A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
WO1999032479A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032486A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (cs) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparentní a semitransparentní difrakční prvky
WO1999055674A1 (en) 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
WO2000066141A2 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
NZ514675A (en) 1999-05-04 2004-05-28 Schering Corp Piperidine derivatives useful as CCR5 antagonists
AU782246B2 (en) 1999-09-13 2005-07-14 Boehringer Ingelheim Pharmaceuticals, Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1221443B1 (en) 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
EP1379506A2 (en) 2000-11-28 2004-01-14 Eli Lilly And Company Substituted carboxamides
US7164024B2 (en) 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
MXPA04006281A (es) 2001-12-28 2004-09-27 Acadia Pharm Inc Analogos de tetrahidroquinolina como agonistas muscarinicos.
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
PT1489078E (pt) 2002-03-28 2010-02-24 Mitsubishi Tanabe Pharma Corp Derivados de benzofurano
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US7265147B2 (en) 2002-07-31 2007-09-04 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
PT1551835E (pt) 2002-09-30 2007-03-30 Neurosearch As Novos derivados de 1, 4-diazabicicloalcano, sua preparação e utilização
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
SG173922A1 (en) 2002-11-27 2011-09-29 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
JPWO2004069828A1 (ja) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
MXPA06000441A (es) 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
ATE428422T1 (de) 2004-02-05 2009-05-15 Schering Corp Piperidin-derivate als ccr3-antagonisten
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006058294A2 (en) 2004-11-29 2006-06-01 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
EP1863490A2 (en) 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
EP2468743A1 (en) 2005-06-24 2012-06-27 Toyama Chemical Co., Ltd. Nitrogen-containing bicyclic compounds useful as antibacterial agents
KR20080087841A (ko) 2005-12-22 2008-10-01 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체의 조절제
JP5512975B2 (ja) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ATE517106T1 (de) 2006-02-22 2011-08-15 Vertex Pharma Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
CA2660903A1 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007338365A1 (en) 2006-12-22 2008-07-03 Novartis Ag 1-Aminomethyl- l- phenyl- cyclohexane derivatives as DDP-IV inhibitors
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
ES2395347T3 (es) 2008-03-27 2013-02-12 Janssen Pharmaceutica, N.V. Derivados de indolilalquilamino sustituidos con aza-biciclohexilo como inhibidores novedosos de histona desacetilasa
EP2344457A1 (en) 2008-10-29 2011-07-20 Grünenthal GmbH Substituted spiroamines
MX2011005150A (es) 2008-12-19 2011-05-30 Boehringer Ingelheim Int Pirimidin-4-carboxamidas ciclicas como antagonistas del receptor ccr2 para el tratamiento de inflamacion, asma y epoc.
ES2528625T3 (es) 2009-04-17 2015-02-11 Janssen Pharmaceutica Nv Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
US20130197027A1 (en) 2010-03-10 2013-08-01 Craig Lindsley Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
AU2011242711C1 (en) 2010-04-22 2016-04-21 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
US8921394B2 (en) 2010-04-27 2014-12-30 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011150183A1 (en) 2010-05-28 2011-12-01 Ge Healthcare Limited Radiolabeled compounds and methods thereof
CA2811525A1 (en) 2010-09-17 2012-03-22 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2012125661A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
CN102354931B (zh) 2011-10-12 2013-08-28 上海电瓷厂 一组多功能构件组成带电作业绝缘工具
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3265459B1 (en) 2015-02-13 2019-05-15 Suven Life Sciences Limited Amide compounds as 5-ht4 receptor agonists
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072705A1 (en) * 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
CN104039321A (zh) * 2011-11-18 2014-09-10 赫普泰雅治疗有限公司 药物化合物
WO2014045031A1 (en) * 2012-09-18 2014-03-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
CN104640851A (zh) * 2012-09-18 2015-05-20 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
WO2014122474A1 (en) * 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2015118342A1 (en) * 2014-02-06 2015-08-13 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.

Also Published As

Publication number Publication date
EP3797778A1 (en) 2021-03-31
JP2018536653A (ja) 2018-12-13
US20220298133A1 (en) 2022-09-22
AU2016348847A1 (en) 2018-06-07
ES2804774T3 (es) 2021-02-09
JP6799596B2 (ja) 2020-12-23
CN108290055A (zh) 2018-07-17
EP3370828B1 (en) 2020-04-15
DK3370828T3 (da) 2020-07-13
WO2017077292A1 (en) 2017-05-11
CN108290055B (zh) 2021-05-14
GB201519352D0 (en) 2015-12-16
HK1253036A1 (en) 2019-06-06
US20200165220A1 (en) 2020-05-28
EP3370828A1 (en) 2018-09-12
US11208396B2 (en) 2021-12-28
US12291512B2 (en) 2025-05-06
CA3003669A1 (en) 2017-05-11
CA3003669C (en) 2024-04-09

Similar Documents

Publication Publication Date Title
AU2016348847B2 (en) Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor
AU2016304387B2 (en) Muscarinic agonists
US10259802B2 (en) Bicyclic aza compounds as muscarinic M1 receptor antagonists
AU2018236871B2 (en) Muscarinic M1 receptor agonists
AU2016302048B2 (en) Muscarinic agonists
AU2015233140A1 (en) Muscarinic receptor agonists
HK1253036B (en) Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor
HK1250138B (en) Muscarinic agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: NXERA PHARMA UK LIMITED

Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED